Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells.

Nature chemical biology - 1 Jul 2026

Hu Lu, Lin Jinyu, Sun Liping, Berezuk Alison M, Tuttle Katharine S, Zhu Xing, Seo Hyuk-Soo, Dhe-Paganon Sirano, Li Pan, Sun Yang, Ni Lisheng, Zhang Jianan, Tan Dazhi, Wakimoto Hiroaki, Cahill Daniel P, Bai Xiaochen, Luo Xuelian, Asara John M, Subramaniam Sriram, Shan Yibing, Wu Xu

Abstract excerpt

Gain-of-function mutations of isocitrate dehydrogenase 1 (IDH1) lead to oncometabolite (R)-2-hydroxyglutarate production, contributing to the tumorigenesis of multiple human cancers. While fatty acid biosynthesis is critical for IDH1-mutant tumor growth, the underlying mechanisms remain unclear. Here, leveraging chemical probes and chemoproteomic profiling, we identified that oncogenic IDH1-R132H is uniquely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Fatty Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to IDH1 gene

Share to Glutarates

Share to Isocitrate Dehydrogenase

Share to Lipoylation

Share to Mutation

Share to Neoplasms

Source

Identifiers

PMID: 41530531
DOI: 10.1038/s41589-025-02131-8

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells.PMID 41530531Read ↗

Catalytically distinct metabolic enzyme isocitrate dehydrogenase 1 mutants tune phenotype severity in tumor models.Semantic proximity Read ↗

Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.Semantic proximity Read ↗

Active site remodeling in tumor-relevant IDH1 mutants drives distinct kinetic features and potential resistance mechanisms.Semantic proximity Read ↗

Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human diseaseSemantic proximity Read ↗

Active site remodeling in tumor-relevant IDH1 mutants drives distinct kinetic features and potential resistance mechanismsSemantic proximity Read ↗

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancerSemantic proximity Read ↗

Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.Semantic proximity Read ↗

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma CellsSemantic proximity Read ↗

Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.Semantic proximity Read ↗

Active site remodeling in tumor-relevant IDH1 mutants drives distinct kinetic features and potential resistance mechanismsSemantic proximity Read ↗

Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.